RT Journal Article
T1 Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case-control sets from EPIC.
A1 Schmidt, Julie A
A1 Fensom, Georgina K
A1 Rinaldi, Sabina
A1 Scalbert, Augustin
A1 Appleby, Paul N
A1 Achaintre, David
A1 Gicquiau, Audrey
A1 Gunter, Marc J
A1 Ferrari, Pietro
A1 Kaaks, Rudolf
A1 Kühn, Tilman
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Karakatsani, Anna
A1 Peppa, Eleni
A1 Palli, Domenico
A1 Sieri, Sabina
A1 Tumino, Rosario
A1 Bueno-de-Mesquita, Bas
A1 Agudo, Antonio
A1 Sanchez-Perez, Maria-Jose
A1 Chirlaque, María-Dolores
A1 Ardanaz, Eva
A1 Larrañaga, Nerea
A1 Perez-Cornago, Aurora
A1 Assi, Nada
A1 Riboli, Elio
A1 Tsilidis, Konstantinos K
A1 Key, Timothy J
A1 Travis, Ruth C
K1 epidemiology
K1 metabolomics
K1 prostate cancer risk
K1 treelet transform
AB Metabolomics may reveal novel insights into the etiology of prostate cancer, for which few risk factors are established. We investigated the association between patterns in baseline plasma metabolite profile and subsequent prostate cancer risk, using data from 3,057 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition (EPIC). We measured 119 metabolite concentrations in plasma samples, collected on average 9.4 years before diagnosis, by mass spectrometry (AbsoluteIDQ p180 Kit, Biocrates Life Sciences AG). Metabolite patterns were identified using treelet transform, a statistical method for identification of groups of correlated metabolites. Associations of metabolite patterns with prostate cancer risk (OR1SD ) were estimated by conditional logistic regression. Supplementary analyses were conducted for metabolite patterns derived using principal component analysis and for individual metabolites. Men with metabolite profiles characterized by higher concentrations of either phosphatidylcholines or hydroxysphingomyelins (OR1SD  = 0.77, 95% confidence interval 0.66-0.89), acylcarnitines C18:1 and C18:2, glutamate, ornithine and taurine (OR1SD  = 0.72, 0.57-0.90), or lysophosphatidylcholines (OR1SD  = 0.81, 0.69-0.95) had lower risk of advanced stage prostate cancer at diagnosis, with no evidence of heterogeneity by follow-up time. Similar associations were observed for the two former patterns with aggressive disease risk (the more aggressive subset of advanced stage), while the latter pattern was inversely related to risk of prostate cancer death (OR1SD  = 0.77, 0.61-0.96). No associations were observed for prostate cancer overall or less aggressive tumor subtypes. In conclusion, metabolite patterns may be related to lower risk of more aggressive prostate tumors and prostate cancer death, and might be relevant to etiology of advanced stage prostate cancer.
YR 2019
FD 2019-04-29
LK http://hdl.handle.net/10668/13793
UL http://hdl.handle.net/10668/13793
LA en
DS RISalud
RD Apr 6, 2025